• Explore /
  • Poster
  • / Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE.

Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX+ bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE.

Abstract Poster

Authors

Ramon Salazar

Ramon Salazar

Oncobell Program IDIBELL Institut Català d'Oncologia Hospital Duran i Reynals, CIBERONC, Hospitalet, Spain

Ramon Salazar , Alfredo Carrato , Teresa Garcia Garcia , Javier Gallego Plazas , Auxiliadora Gómez-España , Cristina Gravalos Castro , M. Pilar Escudero , Maria Jose Safont , Antonieta Salud Salvia , Carles Pericay , Begoña Graña Suárez , David Marrupe , Rosario Vidal , Ferran Losa , Teresa Fernandez Rodriguez , Jose Luis Manzano Mozo , Josep Tabernero , Helder Mansinho , Clara Montagut , Enrique Aranda

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT03635021

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS3618)

DOI

10.1200/JCO.2019.37.15_suppl.TPS3618

Abstract #

TPS3618

Poster Bd #

108b

Abstract Disclosures

Similar Posters

First Author: Joost Huiskens

First Author: Kodai Takemori

First Author: Benoist Chibaudel

Poster

2014 Gastrointestinal Cancers Symposium

Cost differential among systemic therapies for colon cancer.

Cost differential among systemic therapies for colon cancer.

First Author: Hasan Nadeem